{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.19","value":"84.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.64","value":"88.61"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"The Functional Assessment of Cancer Therapy-Head and Neck (FACT H\\&N) consists of 27 core items which assess patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for head and neck related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce subscale scores for each domain. Score range is 0-156. Higher scores denotes better outcomes","dispersionType":"Standard Deviation","groups":[{"description":"Erlotinib\n\nerlotinib hydrochloride\n\npemetrexed disodium\n\nquality-of-life assessment\n\nintensity-modulated radiation therapy","id":"OG000","title":"Erlotinib"}],"paramType":"MEAN","populationDescription":"Data not collected for all participants at 12 months. Data corresponds to Phase II patients.","reportingStatus":"POSTED","timeFrame":"baseline and 12 months","title":"Change in Quality of Life- FACT H&N","type":"SECONDARY","unitOfMeasure":"units on a scale"}